News >

Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer

Danielle Bucco
Published: Thursday, Apr 12, 2018

James R. Mark, MD

James R. Mark, MD
Evidence suggests that androgen deprivation therapy (ADT) increases the risk of cardiovascular disease (CVD) for patients with prostate cancer. It is known that both prostate cancer risk and cardiovascular risk increases with age, but there is also an association between them, according to James R. Mark, MD, an assistant professor at the Sidney Kimmel Cancer Center of Thomas Jefferson University Hospital.

Better FSH control remains one of the benefits of GnRH antagonists, he added. Additionally, there is no microflare, which may prevent a delay in castration-resistant prostate cancer, less PSA progression at 1 year, and fewer cardiac events. However, although the data suggest an improvement in PSA control, this has not translated to an overall survival benefit, says Mark.


  1. Driver JA, Djoussé L, Logroscino G, Gaziano JM, Kurth T. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ. 2008;337:a2467. doi: 10.1136/bmj.a2467.
  2. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868-1876. doi: 10.1200/JCO.2005.04.7423.
  3. Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537-541. doi: 10.1161/CIRCULATIONAHA.115.012519.
  4. Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotrophin release hormone agonists and an antagonist. Eur Urol. 2014;65:565-573.
  5. Klotz L. Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. doi: 10.1111/j.1464- 410X.2008.08183.x.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication